Literature DB >> 6298126

Epstein-Barr virus-specific antibodies in patients with adult T-cell leukemia (ATL) and healthy ATL virus-carriers.

J Imai, Y Hinuma.   

Abstract

Antibodies to Epstein-Barr virus (EBV)-capsid antigen (VCA), early antigen (EA) and EBV-associated nuclear antigen (EBNA) in the sera of 103 patients with adult T-cell leukemia (ATL) and the sera of 243 age- and sex-matched healthy adults, namely 99 anti-ATLA-positive (antibodies to ATL virus-associated antigen) and 144 anti-ATLA-negative individuals, were determined by indirect immunofluorescence. The anti-VCA titers in the sera from ATL patients were within the range observed in healthy controls. Anti-EA was found in 27% of the sera from ATL patients, but in only 8% of the sera from anti-ATLA-negative healthy controls. Antibodies to EBNA, which were present in almost all healthy adults, were not found in 30% of the sera from ATL patients. Of the sera of anti-ATLA-positive healthy adult donors 11% were negative for EBNA antibody. These results suggest that functional impairment of the T-cell system in most ATL patients, and also to a lesser extent in anti-ATLA-positive adults who might be healthy ATLV-carriers, may cause an unusual immune response of antibodies to EBV-associated antigens.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6298126     DOI: 10.1002/ijc.2910310210

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

Review 2.  Malignant lymphomas in Japan: epidemiological analysis of adult T-cell leukemia/lymphoma (ATL).

Authors:  K Tajima
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

3.  Incidence of anti-HTLV-1 antibody in liver disease.

Authors:  H Nakano; M Sata; K Hino; T Aritaka; N Maruyama; T Hino; H Abe; K Tanikawa; M Mizokami
Journal:  Gastroenterol Jpn       Date:  1992-02

4.  Reduced efficacy of treatment of strongyloidiasis in HTLV-I carriers related to enhanced expression of IFN-gamma and TGF-beta1.

Authors:  M Satoh; H Toma; Y Sato; M Takara; Y Shiroma; S Kiyuna; K Hirayama
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

5.  Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica.

Authors:  Brenda M Birmann; Elizabeth C Breen; Sherri Stuver; Beverly Cranston; Otoniel Martínez-Maza; Kerstin I Falk; Akihiko Okayama; Barrie Hanchard; Nancy Mueller; Michie Hisada
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

6.  Predictive markers for development of strongyloidiasis in patients infected with both Strongyloides stercoralis and HTLV-1.

Authors:  M Satoh; S Kiyuna; Y Shiroma; H Toma; A Kokaze; Y Sato
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

7.  The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases.

Authors:  Mari Kannagi; Atsuhiko Hasegawa; Ayako Takamori; Shuichi Kinpara; Atae Utsunomiya
Journal:  Front Microbiol       Date:  2012-09-03       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.